Article
Oncology
Wei Li, Yingying Yang, Menghang Yang, Nan Song, Ziwei Wan, Qing Lu, Jingyun Shi
Summary: This study analyzed the clinicopathologic, radiologic, and prognostic characteristics of primary lung mucinous adenocarcinomas (LMAs) based on radiologic classification. Patients with pure-solid and part-solid types had good prognoses, while those with pneumonic type had poor prognoses.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Koichi Tomoshige, William D. Stuart, Iris M. Fink-Baldauf, Masaoki Ito, Tomoshi Tsuchiya, Takeshi Nagayasu, Tomoki Yamatsuji, Morihito Okada, Takuya Fukazawa, Minzhe Guo, Yutaka Maeda
Summary: The transcription factor FOXA2 has different effects on lung tumorigenesis depending on the oncogenes present. It inhibits tumor development driven by EGFRL858R but promotes tumor growth driven by KRASG12D. Additionally, FOXA2 induces the expression of MUC5AC, leading to the development of invasive mucinous adenocarcinoma (IMA), a subtype of lung cancer.
Article
Cardiac & Cardiovascular Systems
Takuya Matsui, Noriaki Sakakura, Shin Koyama, Keita Nakanishi, Eiichi Sasaki, Seiichi Kato, Waki Hosoda, Yoshiko Murakami, Hiroaki Kuroda, Yasushi Yatabe
Summary: Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma with differences in lymph node metastasis and KRAS mutations compared to non-IMA. Patients with IMA have a higher rate of intrapulmonary recurrence postoperatively, leading to significantly worse prognosis among those with lung recurrence compared to non-IMA patients. Overall survival rates at 5 years did not differ significantly between the two groups.
ANNALS OF THORACIC SURGERY
(2021)
Article
Pathology
Satsuki Kishikawa, Takuo Hayashi, Tsuyoshi Saito, Kazuya Takamochi, Shinji Kohsaka, Kei Sano, Noriko Sasahara, Keita Sasa, Taisei Kurihara, Kieko Hara, Yoshiyuki Suehara, Fumiyuki Takahashi, Kenji Suzuki, Takashi Yao
Summary: This study evaluated the clinicopathological, immunohistochemical, and molecular characteristics of 70 cases of invasive mucinous adenocarcinoma (IMA) of the lung, revealing a significant association between diffuse expression of MUC6 and KRAS-wild-type tumors, smaller tumor size, and female patients. Patients with tumors exhibiting diffuse MUC6 expression had significantly favorable outcomes, suggesting a distinct clinicopathological subset characterized by wild-type KRAS and possibly less aggressive clinical course.
Article
Cardiac & Cardiovascular Systems
Hang Cao, Zelin Ma, Yuan Li, Yang Zhang, Haiquan Chen
Summary: This study comprehensively investigated the clinicopathological characteristics and prognostic value of KRAS G12C mutation in patients with surgically resected lung adenocarcinoma. The results showed that KRAS G12C mutation was more frequent in men, former/current smokers, radiologic solid nodules, invasive mucinous adenocarcinoma, and solid predominant tumors. It was also associated with early and locoregional recurrence.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2023)
Article
Oncology
Daqi Jia, Leilei Li, Peng Wang, Qiang Feng, Xinyan Pan, Peng Lin, Shuling Song, Lilin Yang, Julun Yang
Summary: The study discovered that ZNF24 promotes the growth of KRAS mutant lung adenocarcinoma by upregulating SLC7A5 protein expression, suggesting that ZNF24 may serve as a new biomarker and therapeutic target for KRAS mutant tumors.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Liang Liu, Tamjeed Ahmed, William J. Petty, Stefan Grant, Jimmy Ruiz, Thomas W. Lycan, Umit Topaloglu, Ping-Chieh Chou, Lance D. Miller, Gregory A. Hawkins, Martha A. Alexander-Miller, Stacey S. O'Neill, Bayard L. Powell, Ralph B. D'Agostino, Reginald F. Munden, Boris Pasche, Wei Zhang
Summary: This study revealed that mutations of SMARCA4 serve as a genetic factor leading to adverse clinical outcomes in lung adenocarcinoma, regardless of whether patients were treated with nonimmunotherapy or immunotherapy.
MOLECULAR ONCOLOGY
(2021)
Article
Oncology
Roberto Chalela, Jose Gregorio Gonzalez-Garcia, Karys Khilzi, Victor Curull, Albert Sanchez-Font, Raquel Longaron, Maria Teresa Rodrigo-Calvo, Clara Martin-Ontiyuelo, Joaquim Gea, Beatriz Bellosillo
Summary: Driver mutations in non-tumoral lung cells were detected in a proportion of subjects with ADC, indicating their potential role in carcinogenesis. The presence of these mutations in the absence of coexisting mutations in the primary tumor was confirmed through highly sensitive PCR methods.
PATHOLOGY & ONCOLOGY RESEARCH
(2021)
Article
Pediatrics
Ancuta Muntean, Liliana-Elena Banias, Niyi Ade-Ajayi, Shailesh B. Patel, Olivia McKinney, Mark Davenport
Summary: The aim of this study was to review cases associated with malignancy in congenital pulmonary airway malformation (CPAM). The results showed a clear association between a specific type of CPAM and mucinous adenocarcinoma, and genetic analysis suggested that the process of carcinogenesis could start in utero.
JOURNAL OF PEDIATRIC SURGERY
(2022)
Article
Oncology
Kaiwen Chi, Wei Sun, Xin Yang, Jianghua Wu, Haiyue Wang, Xinying Liu, Luning Mao, Lixin Zhou, Xiaozheng Huang, Dongmei Lin
Summary: This study developed a prognostic classification based on the tumor immunoscore for patients with KRAS-mutant lung adenocarcinoma. The classification showed that histological grading and CD8(+) tumor-infiltrating lymphocytes were independent prognostic factors. The Grading-Immunoscore classification can refine the prognostic grouping and aid in the screening of potential candidates for immunotherapy.
Article
Oncology
Lili Liu, Jia Cui, Siye Liu, Evenki Pan, Limin Sun
Summary: Family history is a known risk factor for lung cancer. Previous studies have identified several germline genetic alterations associated with increased lung cancer risk. This study reports a case of lung adenocarcinoma with a germline ERCC2 frameshift mutation, and highlights the importance of comprehensive genomic profiling in patients with family cancer history.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Manyi Xu, Yue Hao, Huan Zhou, Zheng Shi, Jinfei Si, Zhengbo Song
Summary: Invasive mucinous adenocarcinoma (IMA) is a rare variant of adenocarcinoma characterized by KRAS mutation, and its efficacy of immunotherapy compared to invasive non-mucinous adenocarcinoma (INMA) remains unclear. This study enrolled 65 advanced adenocarcinoma patients with KRAS mutations, and found that IMA was associated with poorer progression-free survival (PFS) compared to INMA. Furthermore, in the IMA subgroup, patients with pure IMA tended to have longer PFS compared to those with mixed mucinous/nonmucinous adenocarcinoma, although the difference was not statistically significant. IMA was identified as an independent risk factor for PFS.
Article
Biochemistry & Molecular Biology
Nguyen Quoc Khanh Le, Quang Hien Kha, Van Hiep Nguyen, Yung-Chieh Chen, Sho-Jen Cheng, Cheng-Yu Chen
Summary: The study introduced a machine learning model for selecting and predicting EGFR and KRAS mutations in NSCLC patients using a minimal number of semantic radiomics features, with the genetic algorithm plus XGBoost classifier showing the best accuracy in detecting these mutations. This noninvasive machine learning-based model demonstrated robust prediction of EGFR and KRAS mutations in patients with NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Junjie Teng, Kai Zhou, Dongxiao Lv, Changshun Wu, Hong Feng
Summary: Targeted therapy and immunotherapy are important treatment options for advanced non-small cell lung cancer (NSCLC). PTEN mutation may serve as a biomarker of resistance to anti-PD-1 immunotherapy in lung adenocarcinoma.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Atish Mohanty, Arin Nam, Saumya Srivastava, Jeff Jones, Brett Lomenick, Sharad S. Singhal, Linlin Guo, Hyejin Cho, Aimin Li, Amita Behal, Tamara Mirzapoiazova, Erminia Massarelli, Marianna Koczywas, Leonidas D. Arvanitis, Tonya Walser, Victoria Villaflor, Stanley Hamilton, Isa Mambetsariev, Martin Sattler, Mohd W. Nasser, Maneesh Jain, Surinder K. Batra, Raffaella Soldi, Sunil Sharma, Marwan Fakih, Saswat Kumar Mohanty, Avijit Mainan, Xiwei Wu, Yihong Chen, Yanan He, Tsui-Fen Chou, Susmita Roy, John Orban, Prakash Kulkarni, Ravi Salgia
Summary: This study reveals non-genetic mechanisms of resistance to sotorasib and proposes a treatment strategy to enhance sensitivity by targeting both ITGB4 and beta-catenin.